ADXS News 2.67 04/26/2014 00:15:16 Advaxis Inc (ADXS)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Advaxis Inc (ADXS) 2.67 $ADXS

Advaxis to Present at 2014 American Society of Clinical Oncology Annual Meeting
GlobeNewswire - Thu Apr 24, 7:45AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, today announced that two abstracts related to ADXS-HPV (ADXS11-001), the Company's lead immunotherapy product candidate, have been selected for poster presentation at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, May 30 - June 3, 2014, at the McCormick Place in Chicago, IL.

Japan Patent Office Issues Advaxis a Notice of Allowance for Two Patent Applications Covering Its Cancer Immunotherapy Platform Technology
GlobeNewswire - Mon Apr 14, 6:30AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced that the Japan Patent Office issued to Advaxis two notices of allowance for two patent applications (P-72863-JP, P-7924) with claims for each patent application related to the Company's proprietary cancer immunotherapy platform technology. These patents will provide protection in Japan until 2030.

Pending Applications, Closed Public Offering, Joint Venture Formation, Executive Appointment, and Commercial Launch - Analyst Notes on Gilead, Enzymotec, Intrexon, Advaxis, and Repligen
PR Newswire - Tue Apr 01, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Gilead Sciences, Inc. (NASDAQ: GILD), Enzymotec Ltd. (NASDAQ: ENZY), Intrexon Corporation (NYSE: XON), Advaxis, Inc. (NASDAQ: ADXS), and Repligen Corporation (NASDAQ: RGEN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Advaxis Receives Notice of Allowance From U.S. Patent and Trademark Office for Three Patent Applications With Multiple Claims Covering Its Cancer Immunotherapy Platform Technology
GlobeNewswire - Tue Apr 01, 6:30AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for three U.S. patent applications (12/213,696, 13/254,607, and 11/415,271) with claims of each application related to the Company's proprietary cancer immunotherapy platform technology. The patent with the latest date of expiry is 2030, without taking into account patent term extension.

Advaxis Announces Closing of Public Offering of Common Stock
GlobeNewswire - Mon Mar 31, 3:37PM CDT
Advaxis, Inc. (Nasdaq:ADXS) ("Advaxis" or the "Company" , today announced the closing of a previously announced underwritten public offering of 4,692,000 shares of its common stock, including the fully exercised over-allotment option by the underwriters covering 612,000 shares, offered at a price to the public of $3.00 per share. The gross proceeds to the Company were $14,076,000, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.

Moskowitz: Advaxis Balance Sheet Shored Up
ACCESSWIRE - Mon Mar 31, 8:40AM CDT
Read the Advaxis Report Update: http://equitiesiq.com/reports/advaxis-update/

Advaxis Announces Full Exercise of Underwriters' Over-Allotment Option
GlobeNewswire - Fri Mar 28, 2:00PM CDT
Advaxis, Inc. (Nasdaq:ADXS) ("Advaxis" or the "Company" , today announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 612,000 shares of its common stock at a public offering price of $3.00 per share in connection with its previously announced underwritten public offering of 4,080,000 shares of common stock, bring the total gross proceeds from the offering to approximately $14,076,000, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.

Team Nation Holdings Corp Officially Changes its Name; Petr Shares Rise on Brazil Outlook Upgrade
ACCESSWIRE - Thu Mar 27, 11:37PM CDT
Petr (NYSE: PBR) - For an in-depth report on Petr follow: www.BullTrends.com/stockquote/PBR

Nasdaq stocks posting largest volume increases
AP - Thu Mar 27, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:

Advaxis Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Wed Mar 26, 7:40PM CDT
Advaxis, Inc. (Nasdaq:ADXS) ("Advaxis" or the "Company" , today announced the pricing of an underwritten public offering of 4,080,000 shares of common stock at a public offering price of $3.00 per share. The Company expects to receive $12,240,000 in gross proceeds, before deducting underwriting discounts and commissions and offering expenses payable by the Company. The Company has granted the underwriters a 45-day option to purchase up to 612,000 additional shares of common stock. The Company intends to use the net proceeds from this offering to fund the Company's continued research and development initiatives in connection with expanding its product line and for other general corporate purposes.

Advaxis Announces Proposed Public Offering of Common Stock
GlobeNewswire - Wed Mar 26, 3:08PM CDT
Advaxis, Inc. (Nasdaq:ADXS) ("Advaxis" or the "Company" , today announced that it intends to offer for sale shares of its common stock in an underwritten public offering. The Company intends to use the net proceeds from this offering to fund the Company's continued research and development initiatives in connection with expanding its product line and for other general corporate purposes. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Advaxis, Inc. [ADXS] to Ring The NASDAQ Stock Market Closing Bell
GlobeNewswire - Wed Mar 26, 11:10AM CDT
What:

Advaxis to Ring The NASDAQ Stock Market Closing Bell
GlobeNewswire - Wed Mar 26, 6:30AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced that its management team will ring The NASDAQ Stock Market Closing Bell on Thursday, March 27, 2014.

Advaxis Appoints Sara Bonstein as Chief Financial Officer, Senior Vice President
GlobeNewswire - Mon Mar 24, 4:16PM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced that it has appointed Sara Bonstein to the position of Chief Financial Officer, Senior Vice President. Ms. Bonstein has a decade of financial leadership experience in the life sciences industry with Eli Lilly & Company, ImClone Systems, and Johnson & Johnson.

Advaxis, Inc. "A Win-Win in Pet Therapeutics"
ACCESSWIRE - Fri Mar 21, 8:21AM CDT
Philadelphia, PA / ACCESSWIRE / March 21, 2014 / Advaxis, Inc. (NASDAQ: ADXS) today published a new blog post on The Chairman's Blog, written by the Company's EVP and COO, Mr. Gregory T. Mayes. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

Advaxis Discusses Global Licensing Agreement for Pet Therapeutics on Conference Call
GlobeNewswire - Thu Mar 20, 11:45AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, hosted a joint conference call with Aratana Therapeutics (Nasdaq ETX) today at 8:00 am ET to discuss the recently announced global licensing agreement for Advaxis's ADXS-cHER2 for the treatment of osteosarcoma in dogs and three additional cancer immunotherapy products for the treatment of three other types of cancer.

Aratana and Advaxis Enter Exclusive Global Licensing Agreement
PR Newswire - Wed Mar 19, 7:01PM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, and Advaxis, Inc. (NASDAQ: ADXS), a biotechnology company developing the next generation of cancer immunotherapies, today announced a global licensing agreement for Advaxis' ADXS-cHER2 for the treatment of osteosarcoma in dogs and three additional cancer immunotherapy products for the treatment of three other types of cancer. Each of the four licensed products is based on Advaxis' platform immunotherapy technology, which Advaxis is developing for the treatment of human cancers on a global basis. Under the agreement, Aratana will have exclusive rights to develop and commercialize the licensed immunotherapies for pet health applications, and will focus initially on developing ADXS-cHER2 for osteosarcoma.

Advaxis Receives Patent in Japan for ADXS-HPV for the Treatment of Cervical Cancer
GlobeNewswire - Tue Mar 18, 6:30AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, today announced that it has been issued a significant patent from the Japan Patent Office, entitled, "Compositions and Methods for Enhancing Immunogenicity of Antigens". The claims of the patent (patent number 5479918) cover the use of ADXS-HPV for the treatment of late-stage cervical cancer with a term that extends to 2028.

Advaxis and UC San Francisco to Evaluate Cancer Immunotherapy Constructs in Prostate Cancer
GlobeNewswire - Mon Mar 17, 6:40AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced that it has signed an agreement with the University of California, San Francisco (UCSF), under which Lawrence Fong, M.D., Professor in the Department of Medicine and principal investigator of the studies at UCSF, will evaluate several new immunotherapy constructs, in addition to ADXS-PSA, each built on the Advaxis proprietary technology. Data generated from this agreement will demonstrate the combination of the unique Advaxis immunotherapy platform, which generates both tumor fighting T cells and reduces tumor protection inside the tumor microenvironment, with targets that have already been shown to be important in effective immunotherapies for prostate cancer.

Advaxis to Present at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum
GlobeNewswire - Thu Mar 13, 8:01AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, today announced that the company will present at the 2 Annual Sachs Cancer Bio Partnering & Investment Forum on Wednesday, March 19 at the New York Academy of Sciences. Robert G. Petit, Ph.D., Chief Scientific Officer of Advaxis, will serve on an expert panel titled "Immunotherapies and Cancer Vaccines" at 11:45am and Daniel J. O'Connor, Chief Executive Officer of Advaxis, will present an update on the Company at 1:30pm.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Dr. Obeng Joins WellcomeMD with Special Offer for Patients

Updated Category News Views 47

New Beginnings in Concierge Medicine In late October, WellcomeMD opened its doors to Dr. Paa-Kofi Obeng—an arrival greeted with considerable anticipation in Richmond's medical scene. This isn't just any run-of-the-mill staff addition; Dr. Obeng brings with him over a decade of experience from places like the Veterans Administration Medical Center. He's armed with a...

Continue Reading
Ross Pools Joins Forces with Florida Panthers in 2026

Updated Category News Views 56

An Unlikely Team-Up: Pools and Hockey Well, here's one for the books: a South Florida pool company hitching its wagon to an NHL team. Ross Pools, the folks who’ve been carving out backyard oases in the sizzling Florida sun for over two decades, are now officially aligned with the Florida Panthers. Yeah, the same Panthers that snatched the Stanley Cup not once but twice...

Continue Reading
Halfday Iced Tea Shakes Up U.S. Retail Scene

Updated Category News Views 142

Halfday's Meteoric Rise in the U.S. Market Sometimes, you pick up a can of iced tea, and it just changes the game. That’s exactly what Halfday is doing, stepping on the accelerator and leaving traditional iced tea brands in the dust. With their latest announcement, they've snagged the title of the fastest-growing modern tea brand in U.S. multi-outlet retail. It's the...

Continue Reading
Webull Faces FINRA Fine and Legal Battle Ahead

Updated Category News Views 187

Webull's Compliance Headache Webull’s been knocked around again. This time, the Financial Industry Regulatory Authority (FINRA) slapped it with a hefty $4.2 million fine. Talk about a hit to the wallet! It all boils down to them failing to roll out some basic anti-money laundering (AML) and other crucial compliance programs. This is no small oversight, and it's got...

Continue Reading
Clinch Scores Big with Two Prestigious Industry Honors

Updated Category News Views 101

Clinch's Dual Triumph in Advertising Innovation No one throws a ticker symbol over their cereal for recognizing brilliance, but when an outfit like Clinch gets double applause at the big dance, even we old-timers have to tip our hats. On November 16, 2026, the advertising world saw some fireworks. Clinch took home not one but two hefty awards—the kind that say you've...

Continue Reading
FDA Changes Shake Up Medtech Inspections Landscape

Updated Category News Views 124

Inspecting the Changing FDA Landscape If you’ve been treating FDA inspections like a ride down memory lane, it's time for a wake-up call. What F. David Rothkopf plans to tell the medical device teams at the MEDevice Silicon Valley event is simple: the game has changed. The FDA’s Quality Management System Regulation (QMSR) that kicked in on February 2, 2026, isn’t...

Continue Reading
Vipshop Prepares for Q3 Financial Results Release

Updated Category News Views 93

Countdown to Vipshop's Third Quarter Results November 24th might just be another day on the calendar for some, but for those of us keeping tabs on the markets, it's a make-or-break moment for Vipshop Holdings Limited. The off-price retail titan from China, trailing under the ticker NYSE:VIPS, is gearing up to swing the doors wide open on its third-quarter financial...

Continue Reading
Luxury Villa Cashback Offers Entice Travelers in November

Updated Category News Views 134

A November Bonanza for Villa Bookings Who doesn't love having a few extra bucks in their pocket, especially when they come with the allure of luxury travel? Villas of Distinction is rolling out what they call a 'November Cashback Offer,' and for those with the wallet—and wanderlust—to match, it could be a tempting proposition. Hanging the bait of up to $2,000 cashback...

Continue Reading
Lennar Faces Securities Fraud Lawsuit: Investor Insights

Updated Category News Views 150

Investors in Lennar: Navigating the Legal Storm Hold onto your hats, folks. Lennar Corporation (NYSE: LEN) is up against it with a brand-spanking-new securities fraud lawsuit helmed by Schall, Brown & Schwartz LLP (SBS). This isn't just a couple of investors grumbling over cocktails; it’s a full-blown class action that’s waving the legal banner under the Securities...

Continue Reading
Tenax Therapeutics Facing Class Action: DEC 28 Deadline

Updated Category News Views 92

Legal Storm Over Tenax Therapeutics Just what the doctor didn't order—legal headaches for Tenax Therapeutics, Inc. (NASDAQ:TENX). Yup, folks, buckle up because we're diving into another class action mudslinging match that’s setting the markets wagging. Berger Montague's law trebuchet is aimed squarely at Tenax and every investor should know the target’s outline....

Continue Reading

Top 5 Most Recently Viewed Articles

Macquarie's Optimistic Outlook for Chinese Internet Stocks

Updated Category News Views 155

Macquarie's Recent Upgrades in the Chinese Internet Sector Macquarie has taken a positive stance on various Chinese internet stocks, highlighting the stronger fundamentals and increased earnings visibility that have emerged in the sector. Analysts believe that ongoing support from the government will further bolster these companies, leading to enhanced growth...

Continue Reading
Highmark Health's Impressive Financial Growth and Future Outlook

Updated Category News Views 238

Highmark Health Reports Impressive Financial Results In a remarkable update, Highmark Health shared its consolidated financial outcomes for the first half of 2025, revealing a revenue of $16.5 billion, alongside a net income of $329 million. This performance is indicative of the organization's robust positioning within the healthcare sector, despite facing ongoing...

Continue Reading
Roblon Reports Steady Q1 Performance Amid Market Challenges

Updated Category News Views 136

Roblon A/S Delivers Steady Financial Results in Q1 2024/25 Roblon’s revenue and earnings for the first quarter of 2024/25 meet expectations The Board of Directors at Roblon A/S has reviewed and approved the interim report reflecting the company’s performance over the initial three months of the financial year 2024/25. This period showcased resilient revenue figures,...

Continue Reading
Weis Markets Achieves Notable Growth in Third Quarter 2025

Updated Category News Views 188

Weis Markets Shows Strong Third Quarter Performance Weis Markets, Inc. (NYSE: WMK) has reported impressive financial results for its third quarter. The company saw an increase of 2.5% in comparable store sales excluding fuel, showcasing its resilience in a fluctuating economic landscape. Overview of Third Quarter Results In the 13-week period ending September 27, 2025,...

Continue Reading
Innovative Renal Care Faces Investigation Over Major Data Breach

Updated Category News Views 156

Innovative Renal Care Under Investigation for Data Breach In recent developments, Innovative Renal Care has come under scrutiny due to a significant data breach that has alarmed both the company and its patients. The investigation, spearheaded by Federman & Sherwood, seeks to uncover the full extent of the incident and understand its implications. Details of the Data...

Continue Reading